Read on Twitter
1/ Our study is out on the @bmj_latest 
TOCILIZUMAB added to the standard of care did not improve clinical outcomes in hospitalized pts with severe Covid19
Let me walk you through the results
TOCILIZUMAB added to the standard of care did not improve clinical outcomes in hospitalized pts with severe Covid19
Let me walk you through the results
2/ Baseline characteristics: ~57yo, around 1/2 of the patients on low flow O2, ~15% on IMV; 20-40% on NIV/HF (random imbalance between groups)
70% of the patients were using steroids at baseline
These pts had high CRP (higher in the control), high LDH, high ferritin:
70% of the patients were using steroids at baseline
These pts had high CRP (higher in the control), high LDH, high ferritin:
3/ Even though, at baseline, the control group seemed to have more severe cases than TOC group (> n. of pts on NIV/HF), the proportion of deaths was higher among TOC group from 8 days of FUP on.
PS:
death but no IMV 
Death causes: ARF or multiorgan system failure
PS:
death but no IMV Death causes: ARF or multiorgan system failure
4/ The darker the purple the worse the outcome at 15 days. Clearly the TOC group did worse than the control group.
5/ This is in contrast to the + effect of TOC seen on REMAP-CAP. Our study is smaller (n=129) but still these contrasting results should be further explored (looking FW to RECOVERY trial data)
Could there b a Covid subgroup that benefits from TOC while another is harmed? (rare)
Could there b a Covid subgroup that benefits from TOC while another is harmed? (rare)
6/ FYI we really looked into details of the data, @damiani_petri can tell, right, Lucas (our super statistician)?
And it does not seem that our result is the result of a bias. Secondary endpoints and sensitivity analyses (not shown) support our results...
And it does not seem that our result is the result of a bias. Secondary endpoints and sensitivity analyses (not shown) support our results...
7/ Link for the article: https://www.bmj.com/content/372/bmj.n84
